Abstract:Epidermal-growth-factor receptor[1] (EGFR) is a polypeptide with 1186 amino acids, which binds to EGF family growth factors. Two major natural ligands in the family interact with EGFR: one is EGF, the other is transforming growth factor-α (TGF-α)[2]. When EGF or TGF-α, binds to EGFR, tyrosine kinase activity is induced which in turn triggers a series of events regulating the cell growth[3-8]. The importance of EGFR in growth regulating pathways was confirmed by the fact that enhanced expression of this receptor was found in brain glioblastomas, breast, lung, ovarian, colorectal, and renal carcinomas[9,10]. Elevated EGFR levels correlated with poor prognosis in human tumors[11-17], for this reason, it seemed to be that EGFR would be a logical target for cancer therapy. Previous reports had shown that monoclonal antibodies to EGFR were effective in the treatment of many human carcinoma cells[18-20]. Other drug therapies which targeted the EGFR had also been successful. Kunkel had shown a drug that inhibited EGFR tyrosine kinase activity could inhibit the growth of A431 cells in nude mice[10]. Yoneda also reported that selective inhibitors of EGFR tyrosine kinase activity, such as tyrphostins, could inhibit the growth of squamous carcinoma in nude mice[21]. Antisense oligodeoxynucleotides inhibit gene expression on a highly selective and target sequence in a specific manner[22-25]. Specific oligonucleotides hybridize to complementary mRNA and decrease protein expression[26-29]. Antisense oligonucleotides against proto-oncogenes of growth factors had already been shown to be successful in cell lines[18,30]. For example, an antisense oligonucleotide to the erB2 gene product had been shown to inhibit protein production in a breast cancer cell line[31]. Akino reported inhibition of in vivo growth and metastases in malignant pituitary tumors with an antisense compound to the PTHrp (parathyroid hormone-related peptide)[32]. An oligonucleotide to the c-myc gene inhibited the growth of thyroid carcinoma cell lines[33]. Phosphorothioate antisense oligodeoxynucleotides targeted against human c-raf-1 kinase producing potent antiproliferative effects on cell culture and in vivo antitumor effects against a variety of tumor types[34]. The co-expression of EGFR along with TGF-α in human colon cancer cell lines, also in colon carcinoma tissue, had led to the suggestion that the autocrine stimulation of EGFR by its ligands could be a mechanism for tumor cells to escape from normal growth controls[35]. Previous studies in our laboratory confirmed over-expression of EGFR in HR8348 cells[36]. In this investigation, we hypothesized that growth and proliferation of HR8348 could be inhibited by EGFR ASODN. In this report 15-mer EGFR ASODN was synthesized and the effects of EGFR ASODN on cell proliferation and tumorigenic rate of HR8348 cells were observed.

Inhibitory Effect of EGFR Antisense Oligodeoxynucleotide on Human Hepatoma Cell Line.

EFFECTS OF DIFFERENT CONCENTRATIONS OF ANTISENSE OLIGODEOXYNUCLEOTIDES(ASODN) ON HUMAN PANCREATIC CANCER CELL LINE PaTu8988s

Inhibitory effect of Hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells

Inhibitory Effects of Egfr Antisense Oligodeoxynucleotide in Human Colorectal Cancer Cell Line

[Effect of HBx Antisense Oligodeoxynucleotide on Formation of Transplanted Hepatocellular Carcinoma in Nude Mice].

Inhibitory Effects of TGF-α Antisense Oligodeoxynucleotide and EGFR Antisense Oligodeoxynucleotide with Liposome on Human Colorectal Cancer Cell Line

[Effects of Vascular Endothelial Growth Factor (VEGF) Antisense Oligodeoxynucleotide on Mrna and Expression of VEGF, Flt-1, and Kinase Insert Domain Containing Receptor and VEGF Excretion in Human Gallbladder Carcinoma Cells].

Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.

[Inhibition Effects of C-Erbb-2 and C-Raf-1 Antisense Oligodeoxynucleotides Combined Transfection on the Human Ovarian Carcinoma Transplanted Subcutaneously in Nude Mice].

Inhibitory Effect Of Human Telomerase Antisense Oligodeoxyribonucleotides On The Growth Of Gastric Cancer Cell Lines In Variant Tumor Pathological Subtype

Antisense epidermal growth factor receptor nanoparticles enhanced radiosensitivity in SCC Ⅶ cells in vitro and in vivo

Inhibitory Effect of Antisense EGFR RNA on the Growth of U251 Glioma Cells

Effect of targeting IL18-EGF fused protein on the antineoplastic activity in vivo

Modulation of Apoptosis, Tumorigenesity and Metastatic Potential with Antisense H-ras Oligodeoxynucleotides in a High Metastatic Tumor Model of Hepatoma: LCI-D20.

Study on the Effects of C-Erbb-2-specific Antisense Oligonucleotides on C-Erbb-2 Overexpressing Breast Cancer Cells

Inhibition of antisense oligonucleotides on EGFR expression and proliferation of RPE cell in vivo

Effects of HSP70 Antisense Oligonucleotide on the Proliferation and Apoptosis of Human Hepatocellular Carcinoma Cells

[Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402].

Inhibitory Effect of Humanized Anti-Vegfr-2 ScFv-As2O3-stealth Nanoparticles Conjugate on Growth of Human Hepatocellular Carcinoma: in Vitro and in Vivo Studies

Antihepatoma Effect of Alpha-Fetoprotein Antisense Phosphorothioate Oligodeoxyribonucleotides in Vitro and in Mice

Inhibitory Effects of Heparanase Antisense Oligodeoxynucleotide on Human Lung Cancer Cells Transplanted Subcutaneously in Nude Mice